Wave Life Sciences Obesity Data Highlights Visceral Fat Focus Over Weight Loss [Yahoo! Finance]
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Wave Life Sciences (NasdaqGM:WVE) released new Phase 1 data for obesity candidate WVE-007 from its INLIGHT study. The therapy showed meaningful reductions in visceral fat and preservation of muscle mass in early testing. Total body weight loss was limited and dose response appeared inconsistent across cohorts. The company plans Phase 2a studies in higher risk populations and is preparing trials that combine WVE-007 with other agents. For investors watching obesity and metabolic drug development, Wave Life Sciences sits at the intersection of RNA medicines and a large, clinically complex disease area. The new WVE-007 readout adds a fresh angle, focusing less on headline weight loss and more on underlying body composition and visceral fat, which are closely tied to cardiometabolic risk. Against a backdrop of growing attention on obesity treatments, the data helps clarify where a smaller p
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Is This Weight Loss Drug Stock a Buy on the Dip? [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Ltd. (WVE) PT Increased to $52 at Canaccord Following Pipeline Review [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Crashes Deep into Oversold Territory as Obesity Drug Data Disappoints. Should You Buy the Dip? [Yahoo! Finance]Yahoo! Finance
- WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Slips as Obesity Data Fails to Convince [Yahoo! Finance]Yahoo! Finance
WVE
Earnings
- 2/26/26 - Miss
WVE
Sec Filings
- 3/30/26 - Form SCHEDULE
- 3/30/26 - Form 4
- 3/26/26 - Form 4
- WVE's page on the SEC website